DE19860132A1 - Use of allergens or allergenic vaccines in the treatment of allergies - Google Patents
Use of allergens or allergenic vaccines in the treatment of allergiesInfo
- Publication number
- DE19860132A1 DE19860132A1 DE1998160132 DE19860132A DE19860132A1 DE 19860132 A1 DE19860132 A1 DE 19860132A1 DE 1998160132 DE1998160132 DE 1998160132 DE 19860132 A DE19860132 A DE 19860132A DE 19860132 A1 DE19860132 A1 DE 19860132A1
- Authority
- DE
- Germany
- Prior art keywords
- vaccines
- allergen
- treatment
- allergoid
- allergies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000013566 allergen Substances 0.000 title claims abstract description 15
- 229960005486 vaccine Drugs 0.000 title claims abstract description 9
- 238000011282 treatment Methods 0.000 title claims abstract description 6
- 206010020751 Hypersensitivity Diseases 0.000 title abstract description 11
- 230000007815 allergy Effects 0.000 title abstract description 11
- 230000002009 allergenic effect Effects 0.000 title 1
- 208000026935 allergic disease Diseases 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 11
- 229940079593 drug Drugs 0.000 claims abstract description 10
- 239000010267 Allergoid Substances 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims abstract description 6
- 239000011505 plaster Substances 0.000 claims abstract description 4
- 239000002674 ointment Substances 0.000 claims abstract description 3
- 229940098465 tincture Drugs 0.000 claims abstract description 3
- 229940126601 medicinal product Drugs 0.000 claims abstract 3
- 238000009169 immunotherapy Methods 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 6
- 238000000586 desensitisation Methods 0.000 abstract description 5
- 230000009885 systemic effect Effects 0.000 abstract description 5
- 238000009109 curative therapy Methods 0.000 abstract description 4
- 238000007920 subcutaneous administration Methods 0.000 abstract description 3
- 229960004784 allergens Drugs 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940021747 therapeutic vaccine Drugs 0.000 description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010048908 Seasonal allergy Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229940074608 allergen extract Drugs 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940046528 grass pollen Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 201000004338 pollen allergy Diseases 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
Abstract
Die Erfindung betrifft die Verwendung von Allergen- und Allergoidvakzinen, deren Abkömmlingen sowie ihren chemischen Verbindungen und Mischungen zur nicht-invasiven epicutan angewendeten transdermalen systemischen Desensibilisierung für die kurative Behandlung vn Allergien. Aufgabe war es, ein Arzneimittel anzugeben, welches die Vorteile der langjährig bewährten, subcutanen systemischen spezifischen Immuntherapie mit denen der nicht-invasiven lokalen Immuntherapie verbindet und gleichzeitig die Nebenwirkungen sehr gering hält mit dem Ziel der spezifischen Desensibilisierung gegen das applizierte Allergen bzw. der kurativen Behandlung der Allergie. DOLLAR A Erfindungsgemäß werden die Allergen- oder Allergoidvakzine, deren Abkömmlinge sowie ihre Verbindungen und Mischungen als epicutan zu verabreichendes, transdermal resorbierbares Arzneimittel, beispielsweise als Salbe, als Tinktur oder in Form eines getränkten Pflasters, für die Behandlung von allergischen Erkrankungen verwendet.The invention relates to the use of allergen and allergoid vaccines, their derivatives and their chemical compounds and mixtures for the non-invasive epicutaneous transdermal systemic desensitization for the curative treatment of allergies. The task was to specify a drug that combines the advantages of long-established, subcutaneous systemic specific immunotherapy with those of non-invasive local immunotherapy and at the same time keeps the side effects very low with the aim of specific desensitization to the applied allergen or curative treatment of allergy. DOLLAR A According to the invention, the allergen or allergoid vaccines, their derivatives and their compounds and mixtures are used as transdermally absorbable medicinal products to be administered epicutaneously, for example as an ointment, as a tincture or in the form of a soaked plaster, for the treatment of allergic diseases.
Description
Die Erfindung betrifft die Verwendung von Allergen- und Allergoid vakzinen, deren chemischen oder physikalischen Abkömmlingen sowie daraus hergestellten Verbindungen und Mischungen zur nicht-invasiven systemischen Desensibilisierung für die kurative Behandlung von Allergien.The invention relates to the use of allergen and allergoid vaccines, their chemical or physical derivatives and compounds and mixtures made therefrom for non-invasive systemic desensitization for the curative treatment of allergies.
Die Immuntherapie mit Allergenextrakten oder -vakzinen ist eine etablierte
Methode, die erstmals 1911 (Noon L., Lancet, 1911; 1 : 1572-73) beschrieben
wurde. Seitdem sind verschiedene Applikationsweisen entwickelt worden. In
Placebo-kontrollierten Doppelblind-Studien wurde zunächst die Wirksamkeit
der systemischen subcutanen spezifischen Immuntherapie bei Wespen
giftallergie (Hunt K. J. et al., N. Engl. J. Med., 1978; 299 : 157-161),
Milbenallergie (Bousquet J., J. Allergy Clin. Immunol., 1985; 76 : 734-744)
und Gräserpollenallergie (Bousquet J., J. Allergy Clin. Immunol., 1987; 80:
591-598) nachgewiesen. Zahlreiche weitere Studien auch mit anderen
Allergenen wurden seitdem publiziert (Übersicht in: Bousquet J. et al., WHO
Position Paper, Allergen Immunotherapy: therapeutic vaccines for allergic
diseases. Allergy, 1998; 53, supplement 44). Wegen zahlreicher teilweise
tödlicher Nebenwirkungen (Commitee on Safety of Medicines. Desensitizing
vaccines. BMJ, 1986; 293 : 948) wurden nebenwirkungsärmere nicht-invasive
Methoden entwickelt. Die am meisten erfolgversprechenden und neben
wirkungsärmsten neuen Applikationsformen sind die nasale und sublinguale
Route, während die orale Verabreichung wegen fraglicher Wirksamkeit und
die bronchiale wegen zu hoher Nebenwirkungsrate nicht empfohlen werden
(Bousquet J. et al., WHO Position Paper, Allergen Immunotherapy:
therapeutic vaccines for allergic diseases. Allergy, 1998; 53, supplement 44:
20-23). Der exakte Wirkmechanismus der spezifischen anti-allergischen
Immuntherapie ist bislang noch nicht geklärt. Es wurden jedoch in
zahlreichen Studien die deutliche Verringerung der allergischen Symptome,
des Medikamentenverbrauchs und des spezifischen Immunglobulin E sowie
eine positive Beeinflussung weiterer immunologischer Parameter nach
gewiesen. Allergene können über die Schleimhäute und in geringerem Maße
über die Haut (transdermal) resorbiert werden. Die Resorption kann durch
verschiedene Zusatzstoffe verbessert werden.Immunotherapy with allergen extracts or vaccines is an established method that was first described in 1911 (Noon L., Lancet, 1911; 1: 1572-73). Since then, various application methods have been developed. In placebo-controlled double-blind studies, the efficacy of systemic subcutaneous specific immunotherapy in wasp poison allergy (Hunt KJ et al., N. Engl. J. Med., 1978; 299: 157-161), mite allergy (Bousquet J., J. Allergy Clin. Immunol., 1985; 76: 734-744) and grass pollen allergy (Bousquet J., J. Allergy Clin. Immunol., 1987; 80: 591-598). Since then, numerous other studies with other allergens have been published (overview in: Bousquet J. et al., WHO Position Paper, Allergen Immunotherapy: therapeutic vaccines for allergic diseases. Allergy, 1998; 53, supplement 44). Because of numerous, sometimes fatal side effects (Committee on Safety of Medicines. Desensitizing vaccines. BMJ, 1986; 293: 948), non-invasive methods with fewer side effects were developed. The most promising and in addition to the least effective new forms of application are the nasal and sublingual route, while oral administration due to questionable effectiveness and bronchial due to excessive side effects are not recommended (Bousquet J. et al., WHO Position Paper, allergen immunotherapy:
therapeutic vaccines for allergic diseases. Allergy, 1998; 53, supplement 44:
20-23). The exact mechanism of action of specific anti-allergic immunotherapy has not yet been clarified. However, numerous studies have demonstrated the significant reduction in allergic symptoms, drug consumption and specific immunoglobulin E as well as a positive influence on other immunological parameters. Allergens can be absorbed through the mucous membranes and to a lesser extent through the skin (transdermally). The absorption can be improved by various additives.
Allergoide sind veränderte Allergene, die eine ähnliche therapeutische Wirkung entfalten wie das ursprüngliche Allergen, deren Verabreichung aber ein geringeres Nebenwirkungsrisiko beinhaltet.Allergoids are modified allergens that have a similar therapeutic It works like the original allergen, but its administration includes a lower risk of side effects.
Der Erfindung liegt die Aufgabe zu Grunde, ein Arzneimittel anzugeben, welches die Vorteile der langjährig bewährten, subcutanen systemischen spezifischen Immuntherapie mit denen der nicht-invasiven lokalen Immuntherapie verbindet und gleichzeitig die Nebenwirkungen sehr gering hält mit dem Ziel der spezifischen Desensibilisierung gegen das applizierte Allergen bzw. der kurativen Behandlung der Allergie.The invention is based on the object of specifying a medicament, which has the advantages of the tried and tested subcutaneous systemic specific immunotherapy with those of non-invasive local Immunotherapy combines and at the same time the side effects are very low holds with the aim of specific desensitization against the applied Allergen or the curative treatment of allergy.
Erfindungsgemäß werden für die Behandlung dieser allergischen Erkran kungen Allergen- oder Allergoidvakzinen, deren chemische oder physikalische Abkömmlinge, einschließlich daraus hergestellter Verbindun gen oder Mischungen, als epicutan zu verabreichendes, transdermal resorbierbares Arzneimittel verwendet. According to the invention for the treatment of this allergic crane allergen or allergoid vaccines, their chemical or physical descendants, including compounds made therefrom genes or mixtures, to be administered epicutaneously, transdermally absorbable drug used.
Die Verabreichung erfolgt beispielsweise durch Pflasterstreifen mit Allergen-/Allergoidvakzine-haltigen Salben, die für mehrere Stunden auf die Haut aufgeklebt werden, oder auch durch die Aufbringung einer entsprechenden Tinktur auf die Haut.The administration takes place, for example, with plaster strips Allergen- / Allergoidvakzine-containing ointments that for several hours on the Skin can be glued on, or by applying a appropriate tincture on the skin.
Die epicutan angewendeten Allergen- und Allergoidvakzinen, deren chemische oder physikalische Abkömmlingen sowie auf ihren Verbindungen oder Mischungen beruhenden Arzneimittel können, wie die bisher gebräuchlichen und oben erwähnten Behandlungen, über mehrere Jahre angewendet werden. Die erste Verabreichung erfolgt mit einer unter schwelligen, nicht-symptom-verursachenden Dosis, die regelmäßig gesteigert wird bis die erwünschte Desensibilisierung erreicht ist.The epicutaneous allergen and allergoid vaccines, their chemical or physical descendants and on their compounds or mixture-based drugs, like those previously Usual and above mentioned treatments, over several years be applied. The first administration takes place with an under swelling, non-symptom-causing dose that is increased regularly until the desired desensitization is reached.
Ein Vorteil der Erfindung ist, daß der Patient die Möglichkeit hat, sich das Arzneimittel im Gegensatz zu subcutanen Injektionen selbst zu verabreichen, und daß somit die Zahl der notwendigen Arztbesuche deutlich reduziert werden kann.An advantage of the invention is that the patient has the opportunity to do this Self-administering medicines as opposed to subcutaneous injections, and that this significantly reduces the number of necessary visits to the doctor can be.
Die Einwirkungszeit des Medikamentes kann mittels getränkter Pflaster streifen im Gegensatz zur sublingualen Applikation erheblich genauer gesteuert werden, denn sie ist nicht vom Schluckverhalten und der Zusam mensetzung des Speichels des Patienten abhängig. Das Pflaster kann für einen eindeutig definierten Zeitraum auf einer exakt definierten Hautstelle aufgetragen werden, so daß die aufgenommene Substratmenge deutlich geringeren Schwankungen unterliegen würde als z. B. bei sublingualer Applikation.The exposure time of the drug can be soaked in plaster in contrast to the sublingual application, streak considerably more precisely can be controlled, because it is not swallowing behavior and togetherness depending on the saliva of the patient. The patch can be used for a clearly defined period of time on a precisely defined area of the skin are applied so that the amount of substrate picked up clearly would be subject to less fluctuations than e.g. B. sublingual Application.
Darüber hinaus stimmen Patienten, insbesondere bei eigener Handhabe möglichkeit des Arzneimittels, einer nicht-invasiven Anwendung des lediglich auf die Haut aufzubringenden Arzneimittels aus Gründen eines geringeren Leidensdrucks eher zu als einer invasiven Behandlung. Auf diese Weise kann der Erkrankung bereits in einem frühen Stadium entgegengewirkt werden.In addition, patients are right, especially with their own handling possibility of the drug, a non-invasive use of the only to be applied to the skin for the sake of a less suffering than invasive treatment. To this Wise, the disease can be counteracted at an early stage become.
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE1998160132 DE19860132A1 (en) | 1998-12-21 | 1998-12-21 | Use of allergens or allergenic vaccines in the treatment of allergies |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE1998160132 DE19860132A1 (en) | 1998-12-21 | 1998-12-21 | Use of allergens or allergenic vaccines in the treatment of allergies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE19860132A1 true DE19860132A1 (en) | 2000-06-29 |
Family
ID=7892708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE1998160132 Withdrawn DE19860132A1 (en) | 1998-12-21 | 1998-12-21 | Use of allergens or allergenic vaccines in the treatment of allergies |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE19860132A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019234032A1 (en) * | 2018-06-06 | 2019-12-12 | Technische Hochschule Mittelhessen | Microemulsion for dermal allergen immunotherapy |
-
1998
- 1998-12-21 DE DE1998160132 patent/DE19860132A1/en not_active Withdrawn
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019234032A1 (en) * | 2018-06-06 | 2019-12-12 | Technische Hochschule Mittelhessen | Microemulsion for dermal allergen immunotherapy |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3856096T2 (en) | Process for the treatment of smoking cessation symptoms associated with smoking cessation and agents for use in this process | |
| DE69012591T2 (en) | Use of nicotine to make a kit for the treatment of disease conditions that respond to nicotine treatment. | |
| EP0913154B1 (en) | Antipsoriatic nail lacquer | |
| EP0773022B3 (en) | Pharmaceutical composition for the treatment of rhinitus, containing sympathomometic and pantothenol and/or pantothenic acid | |
| DE69033112T2 (en) | Sprays containing zinc | |
| EP1917982B1 (en) | Product for the treatment of inflammation, bruises and/or ulcers in the oral area and the use of such a product | |
| DE69411726T2 (en) | COMPOSITIONS FOR RELEASING AN AROMATIC SUBSTANCE INTO THE NOSE | |
| EP0037488A2 (en) | Pharmaceutical composition for healing inflammatory and/or degenerative and/or atrophic mucous membranes | |
| DE69606466T2 (en) | Use of a powder or extract of guava to treat allergies | |
| DE69730214T2 (en) | COMPOSITION AND METHOD FOR THE TREATMENT OF HERPES SIMPLEX | |
| DE69801820T2 (en) | Use of dichlorobenzyl alcohol to make a composition for topical treatment of inflammation | |
| DE19541919A1 (en) | Compositions containing a pantothenol derivative and a sympathomimeticum | |
| CH662510A5 (en) | GLYCYRRHIZINE AND A MEDICINAL PRODUCT CONTAINING AN ACTIVE SUBSTANCE. | |
| WO2001091719A1 (en) | Nasal ointment based on white petroleum jelly | |
| DE60022689T2 (en) | PHARMACEUTICAL DISINFECTANTS CONTAINING USNIC ACID AND AN ESSENTIAL OIL | |
| DE19860132A1 (en) | Use of allergens or allergenic vaccines in the treatment of allergies | |
| DE4300969C2 (en) | Use of Malotilat to accelerate wound healing in case of skin burns | |
| DE69620786T2 (en) | USE OF CHOLINESTERASE INHIBITORS FOR THE PRODUCTION OF A MEDICINE FOR THE TREATMENT OF XEROSTOMY | |
| DE1917283B2 (en) | Manufacture of antimicrobial preparations | |
| DE102012011447A1 (en) | Use of pantothenol or its ester and/or pantothenic acid or its salts together and/or in combination with imidazoline-based alpha-sympathomimetic activity or its salts, used to treat rhinitis and/or to prepare drug for treating rhinitis | |
| CH714586A2 (en) | Green tea-containing mouthwash. | |
| DE3519736C2 (en) | Agents for the treatment of rheumatism and polyarthritis | |
| DE69432703T2 (en) | Use of a composition containing histamine phosphate for the manufacture of a medicament for the topical treatment of epithelial inflammation or lesions | |
| DE112009002721T5 (en) | Antiemetic plaster | |
| DE102017004191A1 (en) | Green tea-containing mouthwash |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8120 | Willingness to grant licenses paragraph 23 | ||
| 8141 | Disposal/no request for examination |